Jason A. Dubovsky

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan et al. · Blood · 2013 · 796 citations

Life Sciences, Immunology, Pharmacology +14

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

David B. Miklos, Corey Cutler, Mukta Arora et al. · Blood · 2017 · 499 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +11

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Jennifer A. Woyach, Engin Bojnik, Amy S. Ruppert et al. · Blood · 2013 · 219 citations

Medicine, Hematology, Oncology +15

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans

Ryan Flynn, Jing Du, Rachelle G. Veenstra et al. · Blood · 2014 · 216 citations · Full text

Life Sciences, Immunology, Pathology +16

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease

Jason A. Dubovsky, Ryan Flynn, Jing Du et al. · Journal of Clinical Investigation · 2014 · 199 citations

Life Sciences, Immunology, Pharmacotherapy +16